Table 3.
Healthcare use and cost of care per patient-year (US dollars, 2016) estimated over 24 months of follow-up (ANRS 12169 2LADY, n = 451)
| Variables | TDF/FTC LPV/r (arm A, n = 152) | ABC ddI LPV/r (arm B, n = 145) | TDF/FTC DRV/r (arm C, n = 154) | p valuea |
|---|---|---|---|---|
| Inpatient care | ||||
| Mean (SD) number of admissions to hospital | 0.0 (0.2) | 0.1 (0.4) | 0.0 (0.2) | 0.90 |
| Mean (SD) cost per patient-year | 2.9 (17.0) | 2.6 (14.9) | 1.4 (8.3) | 0.59 |
| Doctors outpatient consultations | ||||
| Mean (SD) number of consultations | 6.9 (0.5) | 6.9 (0.8) | 6.9 (1.0) | 0.10 |
| Mean (SD) cost per patient-year | 24.0 (13.5) | 27.5 (36.1) | 25.6 (16.6) | 0.99 |
| Biological tests | ||||
| Mean (SD) number of all lab tests | 81.0 (7.0) | 80.7 (11) | 80.6 (11.6) | 0.78 |
| Mean (SD) cost per patient-year | 352.8 (78.6) | 399.2 (452.6) | 366.1 (157.6) | 0.90 |
| Antiretroviral drugs (base-case analysisb) | ||||
| Mean (SD) cost per patient-year | 297.4 (63.4) | 569.8 (114.3) | 552.6 (88.3) | < 0.0001 |
| Burkina Fasoc | 279.5 (6.5) | 515.0 (50.9) | 524.4 (44.5) | < 0.0001 |
| Cameroond | 307.2 (75.1) | 578.4 (126.8) | 554.9 (100.1) | < 0.0001 |
| Senegale | 275.4 (24.2) | 607.5 (83.9) | 586.2 (60.8) | < 0.0001 |
| Drugs for opportunistic infections | ||||
| Mean (SD) number of drugs | 4.7 (5.5) | 4.7 (5.9) | 3.8 (5.6) | 0.12 |
| Mean (SD) cost per patient-year | 9.7 (21.4) | 12.8 (36.1) | 9.0 (22.0) | 0.39 |
| Total cost (base-case analysisb) | ||||
| Mean (SD) cost per patient-year | 686.9 (112.0) | 1011.9 (502.8) | 955.7 (209.5) | < 0.0001 |
| Burkina Fasoc | 566.6 (41.1) | 834.2 (137.7) | 805.2 (40.6) | < 0.0001 |
| Cameroond | 707.1 (105.1) | 1046.6 (594.2) | 966.6 (208.4) | < 0.0001 |
| Senegale | 761.7 (85.7) | 1097.9 (94.7) | 1140.4 (212.5) | < 0.0001 |
ABC ddI LPV/r abacavir + didanosine + lopinavir/ritonavir, SD standard deviation, TDF/FTC DRV/r tenofovir/emtricitabine + darunavir/ritonavir, TDF/FTC LPV/r tenofovir/emtricitabine + lopinavir/ritonavir
aChi square test for categorical variables, and Wilcoxon rank-sum test for continuous variables
bUnit prices of antiretroviral drugs were obtained for the year 2016 from the WHO Global Price Reporting Mechanism database
cn = 90 (30 in arm A, 28 in arm B and 32 in arm C)
dn = 302 (101 in arm A, 99 in arm B and 102 in arm C)
en = 59 (21 in arm A, 18 in arm B and 20 in arm C)